CD8A and neoplasm: IL-33 treatment also drove the induction and cytotoxic activities of DC-induced Tc9 cells, a subset of effector CD8+ T cells producing cytotoxic IL-9, and further promoted the therapeutic efficacy of DC-based tumor vaccines [208].